

DAFTAR PUSTAKA

1. Mat Lazim N, Abdullah B. Risk factors and etiopathogenesis of nasopharyngeal carcinoma. In: Abdullah B, Balasubramanian A, Lazim norhafiza mat, editors. *An Evidence-Based Approach to the Management of Nasopharyngeal Cancer: From Basic Science to Clinical Presentation and Treatment*. United kingdom: Elsevier; 2020. p. 11–30.
2. Lao TD, Le Huyen TA. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: an update report. *Epidemiol Incid Mortal Nasopharynx Cancer Southeast Asia an Updat Rep*. 2020;7(2):86–90.
3. Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2021;30(6):1035–47.
4. Anne W, Lydiatt WM, Colevas D, Glastonbury CM, Thu X Q, Sullivan BO, et al. Nasopharynx. In: Amin M., editor. *AJCC Cancer Staging Manual*. 8th ed. Chicago: American college of surgeons; 2017. p. 103–11.
5. Eu D, Loh T. Benign and malignant tumors of nasopharynx. In: Flint P, editor. *Cummings Otolaryngology Head and Neck Surgery*. 7th ed. Philadelphia: Elsevier; 2021. p. 1391–401.
6. Rahman S, Yerizel E, Khambri D, Tjong DH. Plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma in Minangkabau ethnic group. *AIP Conf Proc*. 2021;2353(1):1–3.
7. Salehiniya H, Mohammadian M, Mahdavi N. Nasopharyngeal cancer in the world: epidemiology , incidence , mortality and risk factors. *World cancer Res J*. 2018;5(1):1–8.
8. Lazim NM, Spinato G, Abdullah K, Rizzo-boscolo P. Survival rates and quality of life of nasopharyngeal carcinoma patients. In: Abdullah B, Balasubramanian A, Lazim norhafiza mat, editors. *An Evidence-Based Approach to the Management of Nasopharyngeal Cancer: From Basic Science to Clinical Presentation and Treatment*. United kingdom: Elsevier; 2020. p. 255–76.
9. Jiromaru R, Nakagawa T, Yasumatsu R. Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options. *Cancer Manag Res*. 2022;14(8):2681–9.
10. Tsang RK, Kwong DL. Nasopharyngeal carcinoma. In: Watkinson J, Clarker R, editors. *Scott-Brown's Otorhinolaryngology and Head and Neck Surgery Volume 3*. 8th Ed. New York: CRC press; 2018. p. 93–113.
11. Chen S, Yang D, Liao X, Lu Y, Yu B, Xu M, et al. Failure Patterns of Recurrence and Metastasis After Intensity-Modulated Radiotherapy in Patients With Nasopharyngeal Carcinoma : Results of a Multicentric Clinical Study. *Front Oncol*. 2022;11(2):1–10.

12. Wong KCW, Hui EP, Lo KW, Lam WKJ, Johnson D, Li L, et al. Nasopharyngeal carcinoma: an evolving paradigm. *Nat Rev Clin Oncol*. 2021;18(11):679–95.
13. Hanahan D, Weinberg RA. Hallmarks of Cancer: An Organizing Principle for Cancer Medicine. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. *Cancer Principles & Practice of Oncology*. 11th ed. USA: Wolters Kluwer; 2019. p. 159–96.
14. Pearson AT, Worden F, Eisbruch A, Sapir E. Chemoradiation for head and neck cancer. In: Wackym P ashley, Snow JB, editors. *Ballanger's otorhinolaryngology head and neck surgery*. 18th Ed. USA: People's medical publishing house; 2016. p. 1361–73.
15. Coluccia M. Cyclooxygenase and Cancer: Fundamental Molecular Investigations. *Int J Mol Sci*. 2023;24(15):1–5.
16. Frejborg E, Salo T, Salem A. Role of cyclooxygenase-2 in head and neck tumorigenesis. *Int J Mol Sci*. 2020;21(23):1–17.
17. Berbecka M, Forma A, Baj J, Furtak-niczyporuk M, Maciejewski R, Sitarz R. A systematic review of the cyclooxygenase-2 (Cox-2) expression in rectal cancer patients treated with preoperative radiotherapy or radiochemotherapy. *J Clin Med*. 2021;10(19):1–21.
18. Chrestella J, Farhat F, Daulay ER, Asnir RA, Yudhistira A, Nasution IA. Cyclooxygenase-2 expression and its correlation with primary tumor size and lymph node involvement in nasopharyngeal carcinoma. *Open Access Maced J Med Sci*. 2018;6(11):2001–5.
19. Ji X, Madhurapantula SV, He G, Wang K, Song C, Zhang J, et al. Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility. *World J Gastroenterol*. 2021;27(28):4653–66.
20. Pu D, Yin L, Huang L, Qin C, Zhou Y, Wu Q, et al. Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer. *Front Oncol*. 2021;11(2):1–7.
21. Zhang Y, Tighe S, Zhu Y-T. COX-2 signaling in the tumor microenvironment. In: Birbrair A, editor. *Tumor Microenvironment Molecular Players - Part B*. Switzerland: Springer; 2020. p. 87–104.
22. Shi C, Guan Y, Zeng L, Liu G, Zhu Y, Xu HE, et al. High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma. *Int J Oncol*. 2018;1(1):1138–48.
23. Farhat, Asnir RA, Yudhistira A, Nurdiansyah F, Yulius S, Daulay ER. Overexpression of Cyclooxygenase-2 in Advanced Stages of Nasopharyngeal Carcinoma. *Stem Cell Oncol*. 2018;1(1):137–41.
24. Farhat F, Daulay ER, Chrestella J. The Association between Cox-2 and MMP-9 with Clinical Staging in NPC Patients. *Int J Nasopharyngeal*

Carcinoma. 2020;2(3):88–92.

25. Li S, Jiang M, Wang L, Yu S. Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers : Recent advancement. Biomed phamacotherapy. 2020;129(6):1–10.
26. Drake RL, Vogt AW, Mitchell AW. Neck. In: Gray's Anatomy for Students. 4th ed. Canada: Elsevier; 2020. p. 989–1075.
27. Dhingra P, Dhingra S. Anatomy and Physiology of Pharynx. In: Diseases of Ear, Nose and Throat & Head and Neck Surgery. 7th Ed. India: Elsevier; 2018. p. 269–73.
28. Wei WI, Chua DTT. Neoplasms of the Nasopharynx. In: Wackym P ashley, Snow JB, editors. Ballanger's otorhinolaryngology head and neck surgery. 18th Ed. USA: People's medical publishing house; 2016. p. 1439–1408.
29. Shah JP, Patel SG, Singh B, Wong RJ. Pharynx and Esophagus. In: Jatin Shah's Head and neck surgery and oncology. Philadelphia: Elsevier; 2020. p. 299–364.
30. Wei WI, Chan J yu wai. Nasopharyngeal carcinoma. In: Sataloff RT, Benninger MS, editors. Sataloff's Comprehensive Textbook of Otolaryngology Head & Neck Surgery; Head and Neck Surgery. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2017. p. 617–45.
31. Tsang CM, Lo KW, Nicholls JM, Huang SCM, Tsao SW, Young LS. Pathogenesis of nasopharyngeal carcinoma : Histogenesis, epstein-barr virus infection, and tumor microenvironment. In: Lee AW., Lung ML, Ng Tong W, editors. Nasopharyngeal Carcinoma: From Etiology to Clinical Practice. Philadelphia: Elsevier; 2019. p. 45–64.
32. Ayele TM, Muche ZT, Teklemariam AB, Kassie AB, Abebe EC. Role of JAK2/STAT3 Signaling Pathway in the Tumorigenesis, Chemotherapy Resistance, and Treatment of Solid Tumors: A Systemic Review. J Inflamm Res. 2022;15(1):1349–64.
33. Wei WI, Chua DT. Nasopharyngeal carcinoma. In: Johnson jonas T, Rosen CA, editors. Bailey's head & neck surgery otolaryngology. 5th Ed. Philadelphia: Wolters Kluwer; 2014. p. 1875–94.
34. Dhingra P, Dhingra S. Tumours of nasopharynx. In: Diseases of Ear, Nose and Throat & Head and Neck Surgery. 7th Ed. India: Elsevier; 2018. p. 279–86.
35. Guo R, Mao Y, Tang L, Chen L, Sun Y, Ma J. Nasopharyngeal carcinoma special feature : Review Article The evolution of nasopharyngeal carcinoma staging. Br Inst Radiol. 2019;1(1):1–9.
36. Gress DM, Edge SB, Greene FL, Washington MK, Asare EA, Brierley JD, et al. AJCC Cancer Staging Manual. In: Amin M., editor. AJCC Cancer Staging Manual. 8th ed. Chicago: American college of surgeons; 2017. p. 3–30.

37. Shah JP, Patel SG, Singh B, Wong RJ. Introduction. In: Jatin Shah's Head and neck surgery and oncology. Philadelphia: Elsevier; 2020. p. 1–14.
38. Ho F, Appalanaido GK. Radiation therapy and chemotherapy in early and advanced nasopharyngeal cancer. In: Abdullah B, Balasubramanian A, Lazim norhafiza mat, editors. An Evidence-Based Approach to the Management of Nasopharyngeal Cancer: From Basic Science to Clinical Presentation and Treatment. United kingdom: Elsevier; 2020. p. 189–221.
39. Vlatković N, Boyd MT. Introducing Molecular Biology of Head and Neck Cancer. In: Watkinson J, Clarker R, editors. Scott-Brown's Otorhinolaryngology and Head and Neck Surgery Volume 3. 8th Ed. New York: CRC press; 2018. p. 55–71.
40. Waes C van. Molecular biology of squamous cell carcinoma. In: Wackym P ashley, Snow JB, editors. Ballanger's otorhinolaryngology head and neck surgery. 18th Ed. USA: People's medical publishing house; 2016. p. 1295–304.
41. Anderson NM, Simon MC. The tumor microenvironment. *Curr Biol.* 2020;30(16):921–5.
42. Bejarano L, Jordão MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. *Cancer Discov.* 2021;11(4):933–59.
43. Su ZY, Siak PY, Leong CO, Cheah SC. Nasopharyngeal Carcinoma and Its Microenvironment: Past, Current, and Future Perspectives. *Front Oncol.* 2022;12(3):1–20.
44. Goradel NH, Najafi M, Salehi E, Farhood B, Mortezaee K. Cyclooxygenase - 2 in cancer : A review. *J Cell Physiol.* 2019;1(1):5683–99.
45. Lee HJ, Kim SR, Jung YJ, Han JA. Cyclooxygenase-2 induces neoplastic transformation by inhibiting p53-dependent oncogene-induced senescence. *Sci Rep.* 2021;11(1):1–13.
46. Amir M, Amin M, Tabari K, Zargari M. MicroRNAs in the anticancer effects of celecoxib : A systematic review. *Eur J Pharmacol.* 2020;1(1):1–7.
47. Souissi S, Ghedira R, Macherki Y, Ben-Haj-Ayed A, Gabbouj S, Remadi Y, et al. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival. *Immunity, Inflamm Dis.* 2022;10(9):1–13.
48. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression — implications for anticancer therapy. *Nat Rev Clin Oncol.* 2019;16(6):356–71.
49. Hibino S, Chikuma S, Kondo T, Ito M, Nakatsukasa H, Omata-mise S, et al. Inhibition pf Nr4a receptors enhances anti-tumor immunity by breaking Treg-mediated immune tolerance. *Am Assoc Cancer Res.* 2018;1(1):2–38.
50. He S, Li Q, Huang Q, Cheng J. Targeting Protein Kinase C for Cancer Therapy. *Cancers (Basel).* 2022;14(5):1–16.

51. Pua LJW, Mai CW, Chung FFL, Khoo ASB, Leong CO, Lim WM, et al. Functional Roles of JNK and p38 MAPK Signaling in Nasopharyngeal Carcinoma. *Int J Mol Sci.* 2022;23(3):1–18.
52. Yousefi H, Vatanmakanian M, Mahdiannasser M, Mashouri L, Alahari N V., Monjezi MR, et al. Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance. *Oncogene.* 2021;40(6):1043–63.
53. Sugiura R, Satoh R, Takasaki T. Erk: A double-edged sword in cancer. erk-dependent apoptosis as a potential therapeutic strategy for cancer. *Cells.* 2021;10(10).
54. Wu Y, Ma J, Sun Y, Tang M, Kong L. Effect and mechanism of PI3K / AKT / mTOR signaling pathway in the apoptosis of GC-1 cells induced by nickel nanoparticles. *Chemosphere.* 2020;255(1):1–11.
55. Hosseini F, Mahdian-Shakib A, Jadidi-Niaragh F, Enderami SE, Mohammadi H, Hemmatzadeh M, et al. Anti-inflammatory and anti-tumor effects of α -L-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model. *Biomed Pharmacother.* 2018;98(1):793–800.
56. Banjara S, Suraweera CD, Hinds MG, Kvansakul M. The Bcl-2 family: Ancient origins, conserved structures, and divergent mechanisms. *Biomolecules.* 2020;10(1):1–21.
57. Li H, Zhang J, Yang Y, Duan S. miR-655: a promising regulator with therapeutic potential. *J Pre-proofs.* 2020;20(6):1–28.
58. Tan IB, Lazim NM, Stoker SD, Wildeman MA. New developments in nasopharyngeal cancer. In: Abdullah B, Balasubramanian A, Lazim norhafiza mat, editors. *An Evidence-Based Approach to the Management of Nasopharyngeal Cancer: From Basic Science to Clinical Presentation and Treatment.* United kingdom: Elsevier; 2020. p. 277–96.
59. Kontomanolis EN, Koutras A, Syllaio A, Schizas D, Mastoraki A, Garmpis N, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: A review. *Anticancer Res.* 2020;40(11):6009–15.
60. Vaezi A, Grandis JR. head and Neck Tumor Biology. In: Johnson jonas T, Rosen CA, editors. *Bailey's Head and Neck Surgery: Otolaryngology.* 5th Ed. Philadelphia: Wolters Kluwer; 2014. p. 1645–71.
61. Zhang Y, Wang X. Targeting the Wnt/ β -catenin signaling pathway in cancer. *J Hematol Oncol.* 2020;13(1):1–16.
62. Ali AH, Haider G, Ahmed K, Hashmi M, Kerio P, Irshad R. Correlation between E-cadherin and hormone receptor status among breast cancer patients. *J Coll Physicians Surg Pakistan.* 2020;30(10):1030–4.
63. Guan S, Wei J, Huang L, Wu L. Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. *Eur J Med Chem.* 2020;207(1):112758.
64. Dewi YA, Anindya ED, Purwanto B. Management of Recurrent

Nasopharyngeal Carcinoma. *Int J nasopharyngeal carcinoma*. 2020;02(04):2019–21.

65. Chang H, Tao Y lan, Ye W jun, Xiao W wei, Xia Y fei, Gao Y hong. Regular aspirin intake and prognosis of TxN2-3M0 nasopharyngeal carcinoma: A cohort study based on propensity score matching. *Oral Oncol*. 2020;103(1):3–8.
66. Tang F, Zhang R, Wang J. Cyclooxygenase-2-Mediated Up-Regulation of Mitochondrial Transcription Factor A Mitigates the Radio-Sensitivity of Cancer Cells. *Int J Mol Sci*. 2019;2(1):1–13.
67. Results CT, Patt YZ. Phase II Trial Using a Combination of Oxaliplatin , Capecitabine , and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer. *Oncologist*. 2018;1(1):1–7.
68. Adetuyi BO, Olajide PA, Adetuyi OA. Preventive phytochemicals of cancer , as speed breakers in inflammatory signaling. *Res J life Sci bioinformatics, Pharm Chem Sci*. 2022;8(31):31–60.
69. Mahboubi Rabbani SMI, Zarghi A. Selective COX-2 inhibitors as anticancer agents: a patent review (2014-2018). *Expert Opin Ther Pat*. 2019;29(6):407–27.
70. Escobar E, Vlanzuela-gomez F, Penafiel C, Hevia-hormazabal A, Herrera-fuentes C, Mori-aliaga D. Immunohistochemical expression of COX-2, Ki-67, Bcl-2, Bax, VEGF and CD105 according to histological grading in oral squamous cell carcinoma. *Patologia (Mex)*. 2023;1(1):1–11.
71. Li WZ, Lv SH, Liu GY, Liang H, Xia WX, Xiang YQ. Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival. *Biol Sex Differ*. 2021;12(1):1–10.
72. Fauzan A, Susilawati S, Larasati V. The Association Between Clinical Characteristics and Histopathology of Nasopharyngeal Carcinoma At Dr. Mohammad Hoesin General Hospital, In 2019-2020. *Biomed J Indones*. 2022;8(1):13–9.
73. Nyangasi MF, McLigeyo AA, Kariuki D, Mithe S, Orwa A, Mwenda V. Decentralizing cancer care in sub-Saharan Africa through an integrated regional cancer centre model: The case of Kenya. *PLOS Glob Public Heal*. 2023;3(1):1–11.
74. Nurada IGK, Ayu IG, Wahyu P. Characteristic of Nasopharyngeal Carcinoma Patients in Mangusada General Hospital in January-December 2019. *Int J Nasopharyngeal Carcinoma*. 2020;02(04):112–4.
75. Zhang W-M, Mo Q-Y, Zhu X-D. Contribution of age at diagnosis to cancer-specific survival of nasopharyngeal carcinoma patients receiving radiotherapy. *Medicine (Baltimore)*. 2023;102(33):1–6.
76. Chan WL, Chow JCH, Xu ZY, Li J, Kwong WTG, Ng WT, et al. Management of Nasopharyngeal Carcinoma in Elderly Patients. *Front*

Oncol. 2022;12(February):1–11.

77. Leus AJG, Haisma MS, Terra JB, Diercks GFH, Van kester MS, Halmos GB, et al. Age-related Differences in Tumour Characteristics and Prognostic Factors for Disease Progression in Cutaneous Squamous Cell Carcinoma of the Head and Neck. *Acta Derm Venereol.* 2022;102(1):1–7.
78. Du J, Feng J, Luo D, Peng L. Prognostic and Clinical Significance of COX-2 Overexpression in Laryngeal Cancer: A Meta-Analysis. *Front Oncol.* 2022;12(4):1–9.
79. Shi C, Guan Y, Zeng L, Liu G, Zhu Y, Xu HE, et al. High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma. *Int J Oncol.* 2018;53(1):1138–48.
80. Zeng X, Liu G, Pan Y. Development and validation of immune inflammation – based index for predicting the clinical outcome in patients with nasopharyngeal carcinoma. *J Cell Mol Med.* 2020;24(2):8326–49.
81. Susilawati S, Kadriyan H, Sutirtayasa WP. Hematologic Profile in Patients with Nasopharyngeal Carcinoma. *Adv Heal Sci Res.* 2022;46(1):110–5.
82. Haque TU, Resident S, Surgery N, Hospital S. Nasopharyngeal Carcinoma - A Clinicopathological Study. *Int J Sci Res.* 2020;9(9):16–7.
83. Susantini IGAD, Adiprayoga NR, Mahayana IBY, Fredlina UTD. Gambaran klinis-histopatologi pasien karsinoma nasofaring di Rumah Sakit Umum Daerah (RSUD) Buleleng pada tahun 2021-Agustus 2023. *Intisari Sains Medis.* 2023;14(3):1064–8.
84. Pontoriero F, Silverman AM, Pascasio JM, Bajaj R. Nonkeratinizing Nasopharyngeal Carcinoma , Undifferentiated Type With Trisomy 2 : A Case Report and Short Review of Cytogenetic and Molecular Literature. *Sage.* 2020;0(0):1–5.
85. Cantù G. Nasopharyngeal carcinoma. A “different” head and neck tumour. Part A: from histology to staging. *Acta Otorhinolaryngol Ital.* 2023;43(2):85–98.
86. Tan KB, Putti TC. Cyclooxygenase 2 expression in nasopharyngeal carcinoma: Immunohistochemical findings and potential implications. *J Clin Pathol.* 2005;58(5):535–8.
87. Peterson BR, Nelson BL. Nonkeratinizing Undifferentiated Nasopharyngeal Carcinoma. *Head Neck Pathol.* 2013;1(1):73–5.
88. Liu Z, Chen Y, Su Y, Hu X, Peng X. Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options. *Front Oncol.* 2021;11(1):1–11.
89. Venkatachala S, Rajendran M. Correlation of COX-2 expression in colorectal carcinoma with clinicopathological features. *Turk Patoloji Derg.* 2017;33(3):228–34.

90. Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, et al. Cyclooxygenase-2 as a target for anticancer drug development. *Crit Rev Oncol Hematol*. 2006;59(1):51–64.
91. Burke HB. Predicting Clinical Outcomes Using Molecular Biomarkers. *Lib Acad*. 2016;1(1):89–99.
92. Lai C, Zhang C, Lv H, Huang H, Ke X, Zhou C, et al. A novel prognostic model predicts overall survival in patients with nasopharyngeal carcinoma based on clinical features and blood biomarkers. *Cancer Med*. 2021;10(11):3511–23.
93. Yoon E, Schwartz C, Brogi E, Ventura K, Wen H, Sloan M, et al. Impact of Biomarkers and Genetic Profiling on Breast Cancer Prognostication: A Comparative Analysis of the Eighth Edition of Breast Cancer Staging System. *Breast J*. 2020;25(5):829–37.
94. Sano Y, Kogashiwa Y, Araki R, Enoki Y, Ikeda T, Yoda T, et al. Correlation of Inflammatory Markers, Survival, and COX2 Expression in Oral Cancer and Implications for Prognosis. *Otolaryngol - Head Neck Surg (United States)*. 2018;158(4):667–76.
95. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. *Int J Mol Sci*. 2022;23(7):1–10.
96. Heshmat-ghahdarjani K, Sarmadi V, Heidari A, Marvasti AF, Neshat S, Raeisi S. The neutrophil-to-lymphocyte ratio as a new prognostic factor in cancers : a narrative review. *Frontiers (Boulder)*. 2023;1(1):1–13.
97. Kurniati I, Arisqan FS, Mutiara UG. Differences in Neutrophil Lymphocyte Ratio (NLR) between Sepsis and Septic Shock Patients in a Tertiary Hospital in Indonesia. *Maj Kedokt Bandung*. 2023;55(3):149–53.
98. Forget P, Khalifa C, Defour JP, Latinne D, Van Pel MC, De Kock M. What is the normal value of the neutrophil-to-lymphocyte ratio? *BMC Res Notes*. 2017;10(1):1–4.
99. Nasry WHS, Rodriguez-Lecompte JC, Martin CK. Role of COX-2/PGE2 mediated inflammation in oral squamous cell carcinoma. *Cancers (Basel)*. 2018;10(10):1–21.
100. de Lima MAP, Cavalcante RB, da Silva CGL, Nogueira RLM, Macedo GEC, de Galiza LE, et al. Evaluation of HPV and EBV in OSCC and the expression of p53, p16, E-cadherin, COX-2, MYC, and MLH1. *Oral Dis*. 2022;28(4):1104–22.
101. Cheki M, Yahyapour R, Farhood B, Rezaeyan A, Shabeeb D, Amini P, et al. COX-2 in Radiotherapy: A Potential Target for Radioprotection and Radiosensitization. *Curr Mol Pharmacol*. 2018;11(3):173–83.
102. Sun N, Wang XQ. Correlation between COX-2 gene polymorphism and susceptibility to nasopharyngeal carcinoma. *Eur Rev Med Pharmacol Sci*.

2019;23(13):5770–8.

103. Rojas A, Lindner C, Schneider I, González I, Araya H, Morales E, et al. Diabetes mellitus contribution to the remodeling of the tumor microenvironment in gastric cancer. *World J Gastrointest Oncol.* 2021;13(12):1997–2012.
104. Shi B, Hu X, He H, Fang W. Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2. *Oncol Lett.* 2021;22(2):1–14.
105. Zhang R, Xie Q, Lu X, Fan R, Tong N. Research advances in the anti-inflammatory effects of SGLT inhibitors in type 2 diabetes mellitus. *Diabetol Metab Syndr.* 2024;16(1):1–15.
106. Wang W, He Q, Zhang H, Zhuang C, Wang Q, Li C, et al. A narrative review on the interaction between genes and the treatment of hypertension and breast cancer. *Ann Transl Med.* 2021;9(10):894–894.
107. Wang W, Ning Y, Wang Y, Deng G, Pace S, Barth SA, et al. Mycobacterium tuberculosis-Induced Upregulation of the COX-2/mPGES-1 Pathway in Human Macrophages Is Abrogated by Sulfasalazine. *Front Immunol.* 2022;13(1):1–13.
108. Kolawole OR, Kashfi K. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. *Int J Mol Sci.* 2022;23(3).
109. Pan J-J, Mai H-Q, Ng WT, Hu C-S, Li J-G, Chen X-Z, et al. Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification. *JAMA Oncol.* 2024;10(12):1627–35.
110. Li Z, Gao Y, An P, Lan F, Wu Y. Proposed modification of the 8th Edition of the AJCC staging system for NPC: A large study in an endemic area. *SSRN.* 2024;1(1):1–34.

